Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum

Rhea-AI Summary

Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, announced that its Chairman and CEO, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023, in New York City. The presentation will take place at 10:00am EST, and management will be available for one-on-one meetings with investors at the conference.

Lishan Aklog, M.D., Chairman & CEO, to Present November 16, 2023, in New York

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced its Chairman and Chief Executive Officer, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023 at 10:00am EST in New York City.

Management will also be available for one-on-one meetings with investors at the conference. Investors who are interested in meeting are encouraged to reach out to their representative at Canaccord Genuity.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test is performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device. EsoGuard and EsoCheck are the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-present-at-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-301975934.html

SOURCE Lucid Diagnostics

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is Lucid Diagnostics Inc.

Who is the Chairman and CEO of Lucid Diagnostics Inc.?

The Chairman and CEO of Lucid Diagnostics Inc. is Dr. Lishan Aklog.

When and where will the presentation take place?

The presentation will take place on November 16, 2023, at 10:00am EST in New York City.

Will management be available for meetings with investors at the conference?

Yes, management will be available for one-on-one meetings with investors at the conference.

How can investors schedule a meeting with Lucid Diagnostics Inc.?

Investors who are interested in meeting are encouraged to reach out to their representative at Canaccord Genuity.